Royce & Associates LP
- SEC CIK
- 0000906304
- Latest filing
- Aug 14, 2026
HALO holding history
Halozyme Therapeutics, Inc. in every 13F filed by Royce & Associates LP, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
HALO overviewAll 13F holders of HALOFull Q2 2026 holdings
- Shares (Q1 2026)
- 0
- Sold out in Q1 2026
- Value
- $0
- % of portfolio
- 0.0%
- Quarters held
- 14
- Since Q1 2022
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q1 2026 | 0 | $0 | 0.0% | −67,000−100.0% | Sold out | Holders |
| Q4 2025 | 67,000 | $4.51M | <0.1% | −7,028−9.5% | Reduced | Holders |
| Q3 2025 | 74,028 | $5.43M | 0.1% | −13,001−14.9% | Reduced | Holders |
| Q2 2025 | 87,029 | $4.53M | <0.1% | −119,612−57.9% | Reduced | Holders |
| Q1 2025 | 206,641 | $13.2M | 0.1% | +9,642+4.9% | Added | Holders |
| Q4 2024 | 196,999 | $9.42M | 0.1% | +72,988+58.9% | Added | Holders |
| Q3 2024 | 124,011 | $7.10M | 0.1% | −52,716−29.8% | Reduced | Holders |
| Q2 2024 | 176,727 | $9.25M | 0.1% | −14,828−7.7% | Reduced | Holders |
| Q1 2024 | 191,555 | $7.79M | 0.1% | +52,245+37.5% | Added | Holders |
| Q4 2023 | 139,310 | $5.15M | <0.1% | +139,310 | New | Holders |
| Q2 2023 | 0 | $0 | 0.0% | −45,000−100.0% | Sold out | Holders |
| Q1 2023 | 45,000 | $1.72M | <0.1% | −51,000−53.1% | Reduced | Holders |
| Q4 2022 | 96,000 | $5.46M | 0.1% | 00.0% | Unchanged | Holders |
| Q3 2022 | 96,000 | $3.80M | <0.1% | 00.0% | Unchanged | Holders |
| Q2 2022 | 96,000 | $4.22M | <0.1% | +64,000+200.0% | Added | Holders |
| Q1 2022 | 32,000 | $1.28M | <0.1% | +32,000 | New | Holders |